InflaRx (IFRX) N.V.announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria, CSU, and hidradenitis suppurativa, HS, investigating the Company’s oral C5aR inhibitor, INF904.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX: